drugset / Trial / NCT04044664
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
Phase 2
Completed
160 enrolled
Aptinyx
Massachusetts General Hospital · collabPremier Research · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
Timeline
- Start
- 2019-01-25
- Primary completion
- 2020-08-05
- Completion
- 2020-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RISEVISTINEL | Small molecule | 10 mg | — |
| Subject | RISEVISTINEL | Small molecule | 50 mg | — |